AEterna Zentaris (TSX:AEZS) Debt-to-Equity : 0.02 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Debt-to-Equity?

AEterna Zentaris's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.22 Mil. AEterna Zentaris's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.16 Mil. AEterna Zentaris's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$24.41 Mil. AEterna Zentaris's debt to equity for the quarter that ended in Dec. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for AEterna Zentaris's Debt-to-Equity or its related term are showing as below:

TSX:AEZS' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.37 Med: 0.01 Max: 0.02
Current: 0.02

During the past 13 years, the highest Debt-to-Equity Ratio of AEterna Zentaris was 0.02. The lowest was -0.37. And the median was 0.01.

TSX:AEZS's Debt-to-Equity is ranked better than
87.5% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs TSX:AEZS: 0.02

AEterna Zentaris Debt-to-Equity Historical Data

The historical data trend for AEterna Zentaris's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Debt-to-Equity Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.37

0.01

0.02

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.02

Competitive Comparison of AEterna Zentaris's Debt-to-Equity

For the Biotechnology subindustry, AEterna Zentaris's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Debt-to-Equity falls into.

AEterna Zentaris Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

AEterna Zentaris's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.215	+	0.16)	/	24.412
	=	0.02

AEterna Zentaris's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.215	+	0.16)	/	24.412
	=	0.02

AEterna Zentaris (TSX:AEZS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

AEterna Zentaris Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.